Pharmacokinetics of Cabotegravir in Subjects with Severe Renal Impairment

BACKGROUND: Cabotegravir (CAB) is an integrase inhibitor in phase 3 clinical trials for the treatment and prevention of HIV. CAB undergoes glucuronidation via UGT1A1 with <1% renal elimination of unchanged CAB. Renal impairment may affect PK of drugs that are primarily metabolized or secreted in...

Descripción completa

Detalles Bibliográficos
Autores principales: Parasrampuria, Ridhi, Ford, Susan, Lou, Yu, Fu, Caifeng, Bakshi, Kalpana, Tenorio, Allan, Trezza, Christine, Spreen, William, Patel, Parul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631309/
http://dx.doi.org/10.1093/ofid/ofx163.1085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631309/
http://dx.doi.org/10.1093/ofid/ofx163.1085

Ejemplares similares